An imaging OEM is teaming with a multi-omics diagnostics company to offer lung-cancer care teams lab data alongside radiologic findings and clinical histories.

Netherlands-based Philips announced the development June 30, saying its Lung Cancer Orchestrator software will now incorporate lung nodule management capabilities developed and marketed by Biodesix, whose home office is in Boulder, Colorado.

The Biodesix product at hand is the company’s Nodify Lung offering, a blood-based toolkit for assessing and tracking cancer risk in lung nodules.

By folding the lab-test component into its Orchestrator dashboard, Philips says it is advancing its vision to “leverage integrated diagnostics from imaging, genomics and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making and help health systems learn from their practice patterns in a dashboard view.”

Biodesix CEO Scott Hutton adds that his company is “delighted that our tests are being incorporated into Philips’ vision for end-to-end cancer care management using a multi-diagnostic approach.”

More from Philips on the development:

Lung cancer remains the leading cause of cancer deaths worldwide, with current five-year survival rates after diagnosis typically less than 20%. If detected and treated early, however, research shows 10-year survival rates could increase to more than 90%. … As a next step after radiologic lung nodule assessment, minimally invasive biopsy procedures such as endobronchial biopsy are already helping early-stage diagnosis. … If a nodule is malignant, the delay in surgical care for cancer patients by four weeks increases the mortality by 6% to 8%.

Full press release here.